undamentalytics Newsletter
Sign in

Scribe Therapeutics, Inc. (SCTX) stock

Add to watchlist

Add holding +

NASDAQ: SCTX Nasdaq Biotechnology Next results ~November 11, 2026

Scribe Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders6 buying, 0 selling8 purchases and 0 sales by directors and officers, last 12 monthsInsider trades

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 30% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Latest results

Earnings per share
-$2.62 against an average estimate of -$3.72: beat by 29.5%
Share reaction
+6.2% in the first session after the results on September 2, 2026, against +1.5% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$1.03

Scribe Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.8%
  • 1 week-0.4%
  • 1 month-7.4%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
September 2, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Governance
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Scribe Therapeutics, Inc. valuation models and calculator

No model value for Scribe Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, after the close. Analysts expect revenue of $4m and EPS of −$1.03 (range −$1.46 to −$0.75) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$5.59 — $12m —
Next −$3.62 +35% $7m −42%

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$3.72 −$2.62 +29.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202644

Counts of recommendations published by analysts covering Scribe Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
—
of tradable shares
Days to cover
1.96
at average volume
Short interest, 1 month
+41%
to October 15, 2026
Held by institutions
61%
of shares
Held by insiders
18.0%
of shares
Employees
82
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−34.5%
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±6.2%
After a week
1 up, 0 down
typical move ±1.6%
After a month
0 up, 1 down
typical move ±42.1%
Results releasedNext dayS&P 500 next day5 days21 days
September 2, 2026 +6.2% +1.5% +1.6% −42.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Insider trading activity

Full insider history and chart
Insider purchases History → $71.3M 8 trades by 6 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $71.3M net buying
Insider Date Trade Shares Price Value
Avoro Ventures Llc Director July 28, 2026 Buy 7,905 $18.25 $144,266
Orbimed Advisors Llc Director July 27, 2026 Buy 1,000,000 $15.00 $15M
Gordon Carl L Director July 27, 2026 Buy 1,000,000 $15.00 $15M
Ah Equity Partners Bio Ii, L.L.C. 10% owner July 27, 2026 Buy 333,333 $15.00 $5M
Avoro Ventures Llc Director July 24, 2026 Buy 2,333,333 $15.00 $35M
Avoro Ventures Llc Director July 24, 2026 Buy 50,000 $22.31 $1.1M
Parrot David Chief Financial Officer July 23, 2026 Buy 1,333 $15.00 $19,995
Lucas Svetlana Chief Business Officer July 23, 2026 Buy 3,000 $15.00 $45,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • September 2, 2026

Recent SEC filings

Data status

When each part of this page on Scribe Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Scribe Therapeutics, Inc. in brief

What does Scribe Therapeutics, Inc. do?
Scribe Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Scribe Therapeutics, Inc.'s stock ticker?
Scribe Therapeutics, Inc. trades under the ticker SCTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Are insiders buying or selling Scribe Therapeutics, Inc. stock?
Over the last 12 months, Scribe Therapeutics, Inc.'s directors and officers reported 8 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Scribe Therapeutics, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Scribe Therapeutics, Inc. announces its own schedule.